<DOC>
	<DOCNO>NCT02907567</DOCNO>
	<brief_summary>This multi-center , randomize , double-blind , placebo-controlled , parallel group study two dos CT1812 adult mild moderate Alzheimer 's Disease evaluate safety tolerability oral CT1812 , administer 28 day . This trial may include 8 qualified investigator sit Australia .</brief_summary>
	<brief_title>Clinical Trial CT1812 Mild Moderate Alzheimer 's Disease</brief_title>
	<detailed_description>Screening procedure occur 42 day . Eligible subject randomize clinic Day 1 receive first dose study drug . Dosing 28 day thereafter off-site total 5 clinic visit treatment period safety lab assessment . Then 7 day post-treatment completion follow-up visit ( Day 35 ) End Study last safety assessment ( Day 49 ) .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>1 . Willing able provide write informed consent prior initiation studyrelated procedure . For subject unable provide write consent , consent provide Person Responsible per local regulation . 2 . Men woman , 5080 year age inclusively diagnosis mild moderate Alzheimer 's disease accord 2011 NIAAA . Women must neither pregnant nursing , either surgically sterile , postmenopausal premenopausal use acceptable method contraception . 3 . Previous decline cognition six month . 4 . Neuroimaging ( MRI ) obtain within previous 6 month screen , consistent clinical diagnosis Alzheimer 's disease . 5 . MMSE 1826 inclusive . 6 . No active depression Geriatric Depression Score ( GDS ) &lt; 6 . 7 . Modified Hachinski Ischemia score â‰¤ 4 . 8 . Formal education eight year . 9 . Living home community set ( assist living ) without continuous nursing care . Each subject must reliable caregiver see least 3 time weekly , oversee administration study drug , willing able participate clinic visit study procedure . Responsible caregiver must provide write informed consent participate . 10 . Concurrent use acetylcholinesterase inhibitor memantine must stable 90 day prior screen expect change . 1 . History screen brain MRI scan indicative significant abnormality , include , limited , prior hemorrhage infarct &gt; 1 cm3 , &gt; 3 lacunar infarct , cerebral contusion , encephalomalacia , aneurysm , vascular malformation , subdural hematoma , hydrocephalus , spaceoccupying lesion ( e.g . abscess brain tumor meningioma ) . 2 . Clinical laboratory finding consistent : 1 . Other primary degenerative dementia , 2 . Other neurodegenerative condition 3 . Seizure disorder 4 . Other infectious , metabolic systemic disease affect central nervous system 3 . A current DSMV diagnosis active major depression , schizophrenia bipolar disorder . 4 . Clinically significant , advanced unstable disease may interfere outcome measure , may bias assessment clinical mental status patient put patient special risk</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>